OnCore Login

Return to Trial Database

HCRN-GU18-343

A Phase 2 Study of CAbozantinib in Combination With AtezolizumaB as NeoAdjuvant Treatment for Muscle-Invasive BladdEr Cancer (ABATE)

Status

Enrollment Closed

Cancer Type(s)

Bladder

Study Contact

(317) 921-2050
studies@hoosiercancer.org

Publications

A phase 2 study of cabozantinib in combination with atezolizumab as neoadjuvant treatment for muscle-invasive bladder cancer ABATE study
  • D Kilari, A Szabo, KA Bylow, RS Alter, AA Nelson, E Lemke, WA Hall, S Johnson, P Langenstroer, K Jacobsohn, NB Davis, C Fung, MI Milowsky
A phase II study of cabozantinib in combination with atezolizumab as neoadjuvant treatment for muscle-invasive bladder cancer (ABATE)
  • M Milowsky, N Davis, C Fung, S Johnson, P Langenstroer, K Jacobsohn, K Bylow, D Kilari

Trial Locations

All sites in which the trial HCRN-GU18-343 being conducted in.
Froedtert & the Medical College of Wisconsin
John Theurer Cancer Center at Hackensack Meridian Health
Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine
University of Rochester Medical Center - Wilmot Cancer Institute
Vanderbilt-Ingram Cancer Center
Virginia Commonwealth University
  • 7676 Interactive Way, Suite 120, Indianapolis, IN 46278